A Phase II Study of Gefitinib in Patients with Metastatic Melanoma

BACKGROUND: Gefitinib is an inhibitor of the epidermal growth factor receptor, which is frequently expressed on both choroidal and non-choroidal melanoma cells. We evaluated the clinical efficacy of gefitinib in patients with metastatic melanoma. METHODS: Patients with stage IV or unresectable stage...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Patel, Sapna P., Kim, Kevin B., Papadopoulos, Nicholas E., Hwu, Wen-Jen, Hwu, Patrick, Prieto, Victor G., Bar-Eli, Menashe, Zigler, Maya, Dobroff, Andrey, Bronstein, Yulia, Bassett, Roland L., Vardeleon, Anna G., Bedikian, Agop Y.
Format: Artigo
Idioma:Inglês
Publicat: 2011
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3132394/
https://ncbi.nlm.nih.gov/pubmed/21738104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CMR.0b013e3283471073
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars